{
    "info": {
        "nct_id": "NCT04623775",
        "official_title": "A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)",
        "inclusion_criteria": "Inclusion Criteria\n\n* Histologically confirmed metastatic non-small cell lung cancer (NSCLC) of squamous (SQ) or non-squamous (NSQ) histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization.\n* Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria.\n* No prior systemic anti-cancer treatment (including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for advanced or metastatic disease.\n\nExclusion Criteria\n\n* Participants with EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy.\n* Untreated CNS metastases.\n* Leptomeningeal metastases (carcinomatous meningitis).\n* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to randomization (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease).\n* Prior treatment with an anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.\n* Other protocol-defined Inclusion/Exclusion criteria apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No prior systemic anti-cancer treatment (including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for advanced or metastatic disease.",
                "criterions": [
                    {
                        "exact_snippets": "No prior systemic anti-cancer treatment (including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for advanced or metastatic disease.",
                        "criterion": "prior systemic anti-cancer treatment for advanced or metastatic disease",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No prior systemic anti-cancer treatment (including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors) given as primary therapy for advanced or metastatic disease.",
                        "criterion": "prior systemic anti-cancer treatment for advanced or metastatic disease",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to randomization (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease).",
                "criterions": [
                    {
                        "exact_snippets": "Concurrent malignancy requiring treatment",
                        "criterion": "concurrent malignancy",
                        "requirement": {
                            "requirement_type": "requiring treatment",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "history of prior malignancy active within 2 years prior to randomization",
                        "criterion": "history of prior malignancy",
                        "requirement": {
                            "requirement_type": "active within years prior to randomization",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease",
                        "criterion": "history of prior malignancy",
                        "requirement": {
                            "requirement_type": "treatment completed before randomization",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease",
                        "criterion": "history of prior malignancy",
                        "requirement": {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Concurrent malignancy requiring treatment",
                        "criterion": "concurrent malignancy",
                        "requirement": {
                            "requirement_type": "requiring treatment",
                            "expected_value": false
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "history of prior malignancy active within 2 years prior to randomization",
                                "criterion": "history of prior malignancy",
                                "requirement": {
                                    "requirement_type": "active within years prior to randomization",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease",
                                        "criterion": "history of prior malignancy",
                                        "requirement": {
                                            "requirement_type": "treatment completed before randomization",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 2,
                                                "unit": "years"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before randomization and the participant has no evidence of disease",
                                        "criterion": "history of prior malignancy",
                                        "requirement": {
                                            "requirement_type": "evidence of disease",
                                            "expected_value": false
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Leptomeningeal metastases (carcinomatous meningitis).",
                "criterions": [
                    {
                        "exact_snippets": "Leptomeningeal metastases (carcinomatous meningitis)",
                        "criterion": "leptomeningeal metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Leptomeningeal metastases (carcinomatous meningitis)",
                        "criterion": "carcinomatous meningitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Leptomeningeal metastases (carcinomatous meningitis)",
                        "criterion": "leptomeningeal metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Leptomeningeal metastases (carcinomatous meningitis)",
                        "criterion": "carcinomatous meningitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Exclusion Criteria",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Participants with EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy.",
                "criterions": [
                    {
                        "exact_snippets": "EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy",
                        "criterion": "gene mutations (EGFR, ALK, ROS-1, BRAF V600E)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy",
                        "criterion": "gene mutations (EGFR, ALK, ROS-1, BRAF V600E)",
                        "requirement": {
                            "requirement_type": "sensitivity to available targeted therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy",
                        "criterion": "gene mutations (EGFR, ALK, ROS-1, BRAF V600E)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "EGFR, ALK, ROS-1, or known B-rapidly accelerated fibrosarcoma proto-oncogene (BRAF V600E) mutations that are sensitive to available targeted therapy",
                        "criterion": "gene mutations (EGFR, ALK, ROS-1, BRAF V600E)",
                        "requirement": {
                            "requirement_type": "sensitivity to available targeted therapy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Inclusion Criteria",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with an anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), anti-programmed death-ligand 2 (PD-L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with an anti-programmed cell death protein 1 (PD-1)",
                        "criterion": "prior treatment with anti-PD-1 antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-programmed death-ligand 1 (PD-L1)",
                        "criterion": "prior treatment with anti-PD-L1 antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-programmed death-ligand 2 (PD-L2)",
                        "criterion": "prior treatment with anti-PD-L2 antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody",
                        "criterion": "prior treatment with anti-CTLA-4 antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways",
                        "criterion": "prior treatment with antibody or drug targeting T-cell co-stimulation or checkpoint pathways",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior treatment with an anti-programmed cell death protein 1 (PD-1)",
                        "criterion": "prior treatment with anti-PD-1 antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-programmed death-ligand 1 (PD-L1)",
                        "criterion": "prior treatment with anti-PD-L1 antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-programmed death-ligand 2 (PD-L2)",
                        "criterion": "prior treatment with anti-PD-L2 antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody",
                        "criterion": "prior treatment with anti-CTLA-4 antibody",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways",
                        "criterion": "prior treatment with antibody or drug targeting T-cell co-stimulation or checkpoint pathways",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Other protocol-defined Inclusion/Exclusion criteria apply.",
                "criterions": [
                    {
                        "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria apply.",
                        "criterion": "other protocol-defined inclusion/exclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria apply.",
                        "criterion": "other protocol-defined inclusion/exclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Untreated CNS metastases.",
                "criterions": [
                    {
                        "exact_snippets": "Untreated CNS metastases",
                        "criterion": "CNS metastases",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Untreated CNS metastases",
                        "criterion": "CNS metastases",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization.",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value at screening",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization.",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "confirmation prior to randomization",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization.",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value at screening",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to 1 at screening and confirmed prior to randomization.",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "confirmation prior to randomization",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria.",
                "criterions": [
                    {
                        "exact_snippets": "Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria.",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria.",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "computed tomography (CT)",
                                "magnetic resonance resources (MRI)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease by computed tomography (CT) or magnetic resonance resources (MRI) per response evaluation criteria in solid tumor version 1.1 (RECIST 1.1) criteria.",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Histologically confirmed metastatic non-small cell lung cancer (NSCLC) of squamous (SQ) or non-squamous (NSQ) histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease.",
                "criterions": [
                    {
                        "exact_snippets": "Histologically confirmed metastatic non-small cell lung cancer (NSCLC)",
                        "criterion": "non-small cell lung cancer (NSCLC)",
                        "requirement": {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Histologically confirmed metastatic non-small cell lung cancer (NSCLC)",
                        "criterion": "non-small cell lung cancer (NSCLC)",
                        "requirement": {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "squamous (SQ) or non-squamous (NSQ) histology",
                        "criterion": "NSCLC histology subtype",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "squamous",
                                "non-squamous"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification)",
                        "criterion": "NSCLC stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "IV A",
                                "IV B"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "recurrent disease following multi-modal therapy for locally advanced disease",
                        "criterion": "recurrent NSCLC after multi-modal therapy for locally advanced disease",
                        "requirement": {
                            "requirement_type": "recurrence after multi-modal therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}